How To Manage Extravasation Of Ibandronic Acid: A Case Report

Öz

Ibandronic acid (IA) is a potent bisphosphonate drug used in the prevention and treatment of osteoporosis. It may also be used to treat hypercalcemia (elevated blood calcium levels). Arthralgia, femur fracture, pain in extremity, diarrhea, myalgia, nausea, back pain, pain, and bone pain are most common adverse events of the IA reported to the FDA. We discourse a case of IA extravasation in this presentation. An osteoporotic woman who was using bifosfonate medications had applied intravenous IA, but almost all of the solution was extravasated accidentally. Two hours later she noticed burning and moderate itching sensation and slight millimeter erythema at the flexure of the right elbow in the region of venipuncture but she had decided not to inform. Although the day after the erythematous area had increased to 5-6 cm and the symptoms worsened, she revisited the outcome clinic. Also, she had a complaint of vomiting and diarrhea. Also, we want to discuss the question of “How this patient's osteoporosis treatment should be continued after this situation?”

Anahtar Kelimeler

• Extravasation,ibandronic acid,management,prevention

How To Manage Extravasation Of Ibandronic Acid?: A Case Report

Öz

Ibandronic acid (IA) is a potent bisphosphonate drug used in the prevention and treatment of osteoporosis. It may also be used to treat hypercalcemia (elevated blood calcium levels). Arthralgia, femur fracture, pain in extremity, diarrhea, myalgia, nausea, back pain, pain, and bone pain are most common adverse events of the IA reported to the FDA. We discourse a case of IA extravasation in this presentation. An osteoporotic woman who was using bifosfonate medications had applied intravenous IA, but almost all of the solution was extravasated accidentally. Two hours later she noticed burning and moderate itching sensation and slight millimeter erythema at the flexure of the right elbow in the region of venipuncture but she had decided not to inform. Although the day after the erythematous area had increased to 5-6 cm and the symptoms worsened, she revisited the outcome clinic. Also, she had a complaint of vomiting and diarrhea. Also, we want to discuss the question of “How this patient's osteoporosis treatment should be continued after this situation?”

Anahtar Kelimeler

• Extravasation,ibandronic acid,management,prevention

Kaynakça

1. 1. Rossini, M., et al., Osteoporosis treatment: why ibandronic acid? Expert Opin Pharmacother, 2013. 14(10): p. 1371-81.2. Guay, D.R., Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy. Pharmacotherapy, 2006. 26(5): p. 655-73.3. Rose, R.F., R & Crawford-Sykes, Annette & Venugopal, R & Wharfe, Gilian & Arscott, George., Extravasation injuries. The West Indian medical journal, 2008. 57(40): p. 7.4. Lewiecki, E.M. and P.D. Miller, Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf, 2007. 6(6): p. 663-72.5. Davis, S., et al., A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess, 2016. 20(78): p. 1-406.6. Veszelyne Kotan, E. and A. Meszaros, [Therapeutic practice of bisphosphonate use and related pharmaceutical issues I]. Acta Pharm Hung, 2016. 86(1): p. 13-22.7. Study of Possible Correlation Between Injection-Site-Extravasation and Ibandronic Acid. Available from: http://factmed.com/study-ibandronic%20acid-causing-injection-site-extravasation.php.8. Zoledronic acid and Extravasation. Available from: https://www.ehealthme.com/ds/zoledronic-acid/extravasation/ 9. Menssen, H.D., et al., Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol, 2002. 20(9): p. 2353-9.10. Diel, I.J., et al., Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer, 2004. 40(11): p. 1704-12.